A review of the treatment of chronic hepatitis C virus infection in cirrhosis

Vezali, Elena; Aghemo, Alessio; Colombo, Massimo

doi:10.1016/s0149-2918(11)00022-1

Cited by 94 publications

(79 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Comment: The rate of SVR with peginterferon plus ribavirin therapy was reported to range from 10 to 44 % for genotypes 1 and 4 and from 33 to 72 % for genotypes 2 and 3 in compensated cirrhosis [55]. Although HCV clearance by the therapy is associated with a reduced risk of liver decompensation, HCC development, and liver-related death [55], these benefits have to be counterbalanced by the increased risk of side effects, such as severe infections in patients with advanced cirrhosis [56].…”

Section: Antiviral Therapy For Hepatitis B Virus Related Cirrhosismentioning

confidence: 99%

“…Although HCV clearance by the therapy is associated with a reduced risk of liver decompensation, HCC development, and liver-related death [55], these benefits have to be counterbalanced by the increased risk of side effects, such as severe infections in patients with advanced cirrhosis [56]. Di Marco et al [57] reported that previous nonresponse to interferon monotherapy did not significantly affect the SVR rate on retreatment with peginterferon alone or peginterferon plus ribavirin therapy.…”

Section: Antiviral Therapy For Hepatitis B Virus Related Cirrhosismentioning

confidence: 99%

See 1 more Smart Citation

Evidence-based clinical practice guidelines for liver cirrhosis 2015

et al. 2016

View full text Add to dashboard Cite

The Japanese Society of Gastroenterology revised the evidence-based clinical practice guidelines for liver cirrhosis in 2015. Eighty-three clinical questions were selected, and a literature search was performed for the clinical questions with use of the MEDLINE, Cochrane, and Igaku Chuo Zasshi databases for the period between 1983 and June 2012. Manual searching of the latest important literature was added until August 2015. The guidelines were developed with use of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. This digest version in English introduces selected clinical questions and statements related to the management of liver cirrhosis and its complications. Branched-chain amino acids relieve hypoalbuminemia and hepatic encephalopathy and improve quality of life. Nucleoside analogues and peginterferon plus ribavirin combination therapy improve the prognosis of patients with hepatitis B virus related liver cirrhosis and hepatitis C related compensated liver cirrhosis, respectively, although the latter therapy may be replaced by direct-acting antivirals. For liver cirrhosis caused by primary biliary cirrhosis and active autoimmune hepatitis, urosodeoxycholic acid and steroid are recommended, respectively. The most adequate modalities for the management of variceal bleeding are the endoscopic injection sclerotherapy for esophageal varices and the balloon-occluded retrograde transvenous obliteration following endoscopic obturation with cyanoacrylate for gastric varices. Beta-blockers are useful for primary prophylaxis of esophageal variceal bleeding. The V 2 receptor antagonist tolvaptan is a useful add-on therapy in careful diuretic therapy for ascites. Albumin infusion is useful for the prevention of paracentesis-induced circulatory disturbance and renal failure. In addition to disaccharides, the nonabsorbable antibiotic rifaximin is useful for the management of encephalopathy. Anticoagulation therapy is proposed for patients with acute-onset or progressive portal vein thrombosis.

show abstract

Section: Antiviral Therapy For Hepatitis B Virus Related Cirrhosismentioning

confidence: 99%

Section: Antiviral Therapy For Hepatitis B Virus Related Cirrhosismentioning

confidence: 99%

Evidence-based clinical practice guidelines for liver cirrhosis 2015

et al. 2016

View full text Add to dashboard Cite

show abstract

“…They found that HCV core antigen-based testing is more cost-effective than HCV RNA testing or no testing at all. Vezali et al (2010) reviewed published evidence and also found that antiviral treatment in cirrhotic patients was less effective than in non-cirrhotic patients, but that eradication of the virus reduced liver complications and improved survival prospects of cirrhotic patients (particularly those with compensated cirrhosis).…”

Section: Health Financing and Insights On Cost-effectivenessmentioning

confidence: 99%

Hepatitis C: Understanding factors that influence the physicians' treatment decisions

Miani¹,

Manville²,

Burge³

et al. 2016

View full text Add to dashboard Cite

“…Direct-acting antivirals were not approved in 2014 in Kazakhstan, and the patient was first considered for antiviral therapy with pegylated interferon alpha-2 with ribavirin for 48 weeks considering genotype 1 HCV with high viremia (9980000 copies/mL), while on a wait list for liver transplant. [1][2][3] However, the decompensated stage of liver cirrhosis (Child-Pugh score of C10, Model for End-Stage Liver Disease score of 13) with ascites, esophageal varices stage 2, anemia, and cytopenia were contraindications for the antiviral treatment with pegylated interferon alpha-2 and ribavirin, and the patient was recommended therapy with the direct-acting antivirals (simeprevir 150 mg and sofosbuvir 400 mg) daily for at least 12 weeks. 4 Because of the unregistered status of these antiviral agents in Kazakhstan, the patient started the antiviral therapy in the United States in June 2014 after ligation of esophageal varices.…”

mentioning

confidence: 99%

Untitled

2016

Exp Clin Transplant

View full text Add to dashboard Cite

A 40-year-old man, diagnosed with decompensated liver cirrhosis because of hepatitis C virus, was on the wait list for a liver transplant when he began treatment with the direct-acting antivirals simeprevir 150 mg and sofosbuvir 400 mg. The patient demonstrated end of treatment virologic response at week 12, normal bilirubin, and alanine aminotransferase levels, resolution of ascites, with downgrading to subcompensated liver cirrhosis, and was removed from the liver transplant wait list. However, the patient did not comply with the recommended duration of the antiviral treatment of at least 16 weeks, which resulted in hepatitis C virus relapse at posttreatment week 12. Later, the patient started an alternative regimen that included a combination of ombitasvir 12.5 mg, paritaprevir 75 mg, ritonavir 50 mg, and dasabuvir 250 mg for 24 weeks and achieved a sustained virologic response. However, despite undetectable hepatitis C virus, the patient began to deteriorate again and was again put on the liver transplant wait list.This first described clinical case in Kazakhstan of successful antiviral therapy with 2 consecutive directacting agents demonstrates the importance of virus eradication of pretransplant survival extension and delaying the need for liver transplant.

show abstract

A review of the treatment of chronic hepatitis C virus infection in cirrhosis

Cited by 94 publications

References 84 publications

Evidence-based clinical practice guidelines for liver cirrhosis 2015

Evidence-based clinical practice guidelines for liver cirrhosis 2015

Hepatitis C: Understanding factors that influence the physicians' treatment decisions

Untitled

Contact Info

Product

Resources

About